title: Performance of the resolute zotarolimus-eluting stent in small vessels.
abstract: BACKGROUND
  Drug eluting stents for the treatment of small vessel coronary artery disease have traditionally yielded inferior clinical outcomes compared to the use of DES in large vessels. The benefit of the second-generation Resolute zotarolimus-eluting stent (R-ZES) in small vessels was examined.
  
  
  METHODS
  Two-year clinical outcomes from five combined R-ZES studies were compared between patients with small (reference vessel diameter [RVD] ≤2.5 mm; n = 1,956) and large (RVD >2.5 mm; n = 3174) vessels.
  
  
  RESULTS
  Despite a higher incidence of comorbidities in the small vessel group, there was no significant difference in target lesion failure (TLF) (10.1% vs. 8.7%; P = 0.54) at 2 years. When the subgroup of patients with diabetes was examined (n = 1,553) there was no significant difference in 2-year TLF in small compared to large vessels (11.2% vs. 11.1%; P = 0.17). Similarly, within the small vessel cohort, no significant difference was seen regarding TLF at 2 years between people with and without diabetes (11.2% vs 9.6%; P = 0.28).
  
  
  CONCLUSIONS
  When used for the treatment of small vessels, the R-ZES appears to provide acceptable clinical results at 2 years when compared to its performance in large vessels.
authors.affiliation: St. Joseph's Hospital Cardiology, Liverpool, New York, New York.
authors.forename: Ronald
authors.initials: R
authors.lastname: Caputo
authors.forename: Martin
authors.initials: M
authors.lastname: Leon
authors.forename: Patrick
authors.initials: P
authors.lastname: Serruys
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Neumann
authors.forename: Alan
authors.initials: A
authors.lastname: Yeung
authors.forename: Stephan
authors.initials: S
authors.lastname: Windecker
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Belardi
authors.forename: Sigmund
authors.initials: S
authors.lastname: Silber
authors.forename: Ian
authors.initials: I
authors.lastname: Meredith
authors.forename: Petr
authors.initials: P
authors.lastname: Widimský
authors.forename: Shigeru
authors.initials: S
authors.lastname: Saito
authors.forename: Laura
authors.initials: L
authors.lastname: Mauri
mesh_terms: D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000601:surgery*; D003331:Coronary Vessels / Q000601:surgery*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C489443:zotarolimus; D020123:Sirolimus
keywords: coronary artery disease; diabetes; drug eluting stent; small vessel disease